The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed

Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed

December 2, 2021 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—For patients with myositis for whom initial therapies fail to control symptoms, the first step in determining the next therapeutic approach is to determine whether the symptoms are due to active disease or damage.

You Might Also Like
  • Myositis Management: Clinical Trials Provide New Insights into Treatment Options
  • Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis
  • From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management
Also By This Author
  • Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

If inflammation is persistent, “re-evaluate the diagnosis,” said Ingrid E. Lundberg, MD, PhD, Division of Rheumatology, Department of Medicine, Karolinska Institutet, Solna, Stockholm. However, she continued, “if persisting inflammation and other disorders have been ruled out, change therapy.”

Dr. Lundberg

These are the key steps to take when assessing management of a patient with inflammatory myositis refractory to initial therapies, based on newly published algorithms developed to help rheumatologist manage these patients.1 In a session titled Management of Inflammatory Myositis Refractory to Initial Therapies, Dr. Lundberg used a case study to illustrate how the algorithms can be used to help differentiate the cause of persistent inflammation in these patients and treatment considerations based on what is determined (see Figure 1 below for one of the algorithms).

Figure 1

Algorithm for a diagnostic approach for patients with refractory idiopathic inflammatory myopathy (IIM) with persistent muscle weakness. MMT = Manual Muscle Testing; FI = Functional Index in myositis; CK = creatine kinase; LDH = lactate dehydrogenase; MRI = magnetic resonance imaging; MSA = myositis-specific autoantibody; MAA = myositis-associated autoantibody; IBM = inclusion body myositis.

[mobile-ad name="Advert 2"]

Reprinted by permission from Lundberg IE. Expert perspective: Management of refractory inflammatory myopathy. Arthritis Rheumatol.1

Dr. Lundberg opened the session by emphasizing the heterogeneous and often systemic nature of inflammatory myositis that can affect more than the muscles, and include the skin, lung, joints and heart. However, she said, autoantibodies detected in past decades have identified more homogenous disease groups associated with certain myositis-specific autoantibodies (MSA) found in both adult and juvenile disease. These MSAs were found in up to 50% of some cohort studies.

To date, few randomized controlled trials are available to guide treatment. In the absence of such evidence, she recommends turning to expert opinion that provides guidance on first-, second- and third-line therapies.2 All three lines of therapy include glucocorticoids, with or without intravenous immunoglobulin (IVIG) therapy, but they differ with regard to biologic agents suggested.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For patients for whom first-line therapy with methotrexate or azathioprine fails, Dr. Lundberg said the recommended second-line therapy is mycophenolate mofetil (MMF), tacrolimus or cyclosporine or combination therapy of methotrexate and azathioprine.

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2021, myositis, patient care

You Might Also Like:
  • Myositis Management: Clinical Trials Provide New Insights into Treatment Options
  • Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis
  • From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management
  • Tips for Myositis Management

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)